Alli M Straubhar1, Olga T Filippova1, Renee A Cowan1, Yulia Lakhman2, Debra M Sarasohn2, Ines Nikolovski2, Jean M Torrisi2, Weining Ma2, Nadeem R Abu-Rustum3, Ginger J Gardner3, Yukio Sonoda3, Oliver Zivanovic3, Dennis S Chi3, Kara Long Roche4. 1. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Obstetrics & Gynecology, Weill Cornell Medical College, New York, NY, USA. 4. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Obstetrics & Gynecology, Weill Cornell Medical College, New York, NY, USA. Electronic address: longrock@mskcc.org.
Abstract
OBJECTIVE: To describe outcomes using a multimodal algorithm to triage patients with advanced epithelial ovarian cancer (EOC) to primary debulking surgery (PDS) versus neoadjuvant chemotherapy (NACT). METHODS: All patients with EOC treated at our institution from 04/2015-08/2018 were identified. We included patients without contraindication to PDS who underwent prospective calculation of a Resectability (R)-score. A low risk score for suboptimal cytoreduction was defined as ≤6, and a high risk score ≥7. Patients were triaged to laparotomy/PDS, laparoscopic evaluation of resectability (LSC), or NACT depending on R-score. RESULTS: Among 299 participants, 226 (76%) had a low risk score and 73 (24%) a high risk score. For patients with a low risk score, management included laparotomy/PDS, 181 (80%); LSC, 43 (19%) (with subsequent triage: PDS, 31; NACT, 12); and NACT, 2 (1%). For patients with a high risk score, management included laparotomy/PDS, 9 (12%); LSC, 51 (70%) (with subsequent triage: PDS, 28; NACT, 23); and NACT, 13 (18%). Overall, 83% underwent PDS, with a 75% CGR rate and 94% optimal cytoreduction rate. Use of the algorithm resulted in a 31% LSC rate and a 6% rate of suboptimal PDS. CONCLUSIONS: The multimodal algorithm led to excellent surgical results; 94% of patients achieved an optimal resection, with a very low rate of suboptimal cytoreduction.
OBJECTIVE: To describe outcomes using a multimodal algorithm to triage patients with advanced epithelial ovarian cancer (EOC) to primary debulking surgery (PDS) versus neoadjuvant chemotherapy (NACT). METHODS: All patients with EOC treated at our institution from 04/2015-08/2018 were identified. We included patients without contraindication to PDS who underwent prospective calculation of a Resectability (R)-score. A low risk score for suboptimal cytoreduction was defined as ≤6, and a high risk score ≥7. Patients were triaged to laparotomy/PDS, laparoscopic evaluation of resectability (LSC), or NACT depending on R-score. RESULTS: Among 299 participants, 226 (76%) had a low risk score and 73 (24%) a high risk score. For patients with a low risk score, management included laparotomy/PDS, 181 (80%); LSC, 43 (19%) (with subsequent triage: PDS, 31; NACT, 12); and NACT, 2 (1%). For patients with a high risk score, management included laparotomy/PDS, 9 (12%); LSC, 51 (70%) (with subsequent triage: PDS, 28; NACT, 23); and NACT, 13 (18%). Overall, 83% underwent PDS, with a 75% CGR rate and 94% optimal cytoreduction rate. Use of the algorithm resulted in a 31% LSC rate and a 6% rate of suboptimal PDS. CONCLUSIONS: The multimodal algorithm led to excellent surgical results; 94% of patients achieved an optimal resection, with a very low rate of suboptimal cytoreduction.
Authors: Anna Fagotti; Gabriella Ferrandina; Francesco Fanfani; Alfredo Ercoli; Domenica Lorusso; Marco Rossi; Giovanni Scambia Journal: Ann Surg Oncol Date: 2006-06-21 Impact factor: 5.344
Authors: Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: Philipp Harter; Zelal M Muallem; Christine Buhrmann; Dietmar Lorenz; Christine Kaub; Rita Hils; Stefan Kommoss; Florian Heitz; Alexander Traut; Andreas du Bois Journal: Gynecol Oncol Date: 2011-03-17 Impact factor: 5.482
Authors: Rudy S Suidan; Pedro T Ramirez; Debra M Sarasohn; Jerrold B Teitcher; Revathy B Iyer; Qin Zhou; Alexia Iasonos; John Denesopolis; Oliver Zivanovic; Kara C Long Roche; Yukio Sonoda; Robert L Coleman; Nadeem R Abu-Rustum; Hedvig Hricak; Dennis S Chi Journal: Gynecol Oncol Date: 2017-02-14 Impact factor: 5.482
Authors: Marianne J Rutten; Hannah S van Meurs; Roelien van de Vrie; Katja N Gaarenstroom; Christiana A Naaktgeboren; Toon van Gorp; Henk G Ter Brugge; Ward Hofhuis; Henk W R Schreuder; Henriette J G Arts; Petra L M Zusterzeel; Johanna M A Pijnenborg; Maarten van Haaften; Guus Fons; Mirjam J A Engelen; Erik A Boss; M Caroline Vos; Kees G Gerestein; Eltjo M J Schutter; Brent C Opmeer; Anje M Spijkerboer; Patrick M M Bossuyt; Ben Willem Mol; Gemma G Kenter; Marrije R Buist Journal: J Clin Oncol Date: 2016-12-28 Impact factor: 44.544
Authors: Rudy S Suidan; Pedro T Ramirez; Debra M Sarasohn; Jerrold B Teitcher; Svetlana Mironov; Revathy B Iyer; Qin Zhou; Alexia Iasonos; Harold Paul; Masayoshi Hosaka; Carol A Aghajanian; Mario M Leitao; Ginger J Gardner; Nadeem R Abu-Rustum; Yukio Sonoda; Douglas A Levine; Hedvig Hricak; Dennis S Chi Journal: Gynecol Oncol Date: 2014-07-11 Impact factor: 5.482
Authors: Alli M Straubhar; Jennifer L Wolf; Ms Qin C Zhou; Alexia Iasonos; Stephanie Cham; Jason D Wright; Kara Long Roche; Dennis S Chi; Oliver Zivanovic Journal: Gynecol Oncol Date: 2020-12-04 Impact factor: 5.482